Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.

JAMA Internal Medicine
Yao QiaoMorgan E Grams

Abstract

It is uncertain whether and when angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin II receptor blocker (ARB) treatment should be discontinued in individuals with low estimated glomerular filtration rate (eGFR). To investigate the association of ACE-I or ARB therapy discontinuation after eGFR decreases to below 30 mL/min/1.73 m2 with the risk of mortality, major adverse cardiovascular events (MACE), and end-stage kidney disease (ESKD). This retrospective, propensity score-matched cohort study included 3909 patients from an integrated health care system that served rural areas of central and northeastern Pennsylvania. Patients who initiated ACE-I or ARB therapy from January 1, 2004, to December 31, 2018, and had an eGFR decrease to below 30 mL/min/1.73 m2 during therapy were enrolled, with follow-up until January 25, 2019. Individuals were classified based on whether they discontinued ACE-I or ARB therapy within 6 months after an eGFR decrease to below 30 mL/min/1.73 m2. The association between ACE-I or ARB therapy discontinuation and mortality during the subsequent 5 years was assessed using multivariable Cox proportional hazards regression models, adjusting for patient characteristics at the time of the eGFR decre...Continue Reading

References

Jun 21, 2001·JAMA : the Journal of the American Medical Association·L Y AgodoaUNKNOWN African American Study of Kidney Disease and Hypertension (AASK) Study Group
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Oct 11, 2001·Journal of Hypertension·R MarinUNKNOWN Investigators of the ESPIRAL Study. Efecto del tratamiento antihipertensivo Sobre la Progresión de la Insuficiencia RenAL en
Dec 8, 2004·Journal of the American Society of Nephrology : JASN·Giuseppe RemuzziUNKNOWN RENAAL Study Group
Jan 13, 2006·The New England Journal of Medicine·Fan Fan HouRen Wen Geng
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Oct 13, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Aimun K AhmedA Meguid El Nahas
Jun 26, 2010·Cardiovascular Drugs and Therapy·Roberto FerrariClaudio Ceconi
Sep 8, 2011·Perspectives in Clinical Research·Sandeep K Gupta
Feb 15, 2013·Prevention Science : the Official Journal of the Society for Prevention Research·Weiwei LiuElizabeth A Stuart
Nov 26, 2013·Journal of the American College of Cardiology·Miklos Z MolnarCsaba P Kovesdy
Nov 26, 2015·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Xinfang XieHaiyan Wang
Jan 2, 2016·International Journal of Epidemiology·Lauren E CainUNKNOWN Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems, and the H
Aug 22, 2017·JAMA Oncology·Louise EmilssonMiguel A Hernán
Jul 14, 2018·Clinical Journal of the American Society of Nephrology : CJASN·Jung-Im ShinMorgan E Grams
Jul 2, 2019·Journal of the American Heart Association·Prashant PatelVishal C Mehra

❮ Previous
Next ❯

Citations

Mar 18, 2020·Journal of Diabetes·Zachary Bloomgarden
Jul 19, 2020·Journal of Clinical Medicine·Luca De NicolaRoberto Minutolo
Sep 24, 2020·JAMA Surgery·Kaifeng Liang, Zheyuan Chen
May 7, 2020·Endocrinology and Metabolism·Eun Jung RheeWon Young Lee
Jul 11, 2020·Current Cardiology Reports·Waleed Ali, George Bakris
Apr 3, 2020·European Heart Journal. Cardiovascular Pharmacotherapy·Giovanni de Simone, Costantino Mancusi
Jan 29, 2021·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·José Luis GorrizJulio Núñez
Feb 12, 2021·Heart·Julio Alejandro Lamprea-MontealegreMichelle M Estrella
Nov 9, 2020·Mayo Clinic Proceedings·Biff F PalmerMatthew R Weir
Dec 29, 2020·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Carl P WaltherSankar D Navaneethan
Dec 30, 2020·Journal of the American Society of Nephrology : JASN·Edouard L FuJuan J Carrero
Dec 11, 2020·Diabetes Care·UNKNOWN American Diabetes Association
Feb 21, 2021·Clinical Journal of the American Society of Nephrology : CJASN·Jonathan A Bolaños, Stephen L Seliger
Feb 28, 2021·Kidney International·UNKNOWN Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group
Mar 24, 2021·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Elias SanidasJohn Barbetseas
Mar 25, 2021·Medicina clínica·Ana María García-PrietoMarian Goicoechea
May 11, 2021·Journal of the American Heart Association·Derrick T AntoniakVenkata M Alla
Jul 3, 2021·Journal of Clinical Medicine·Prasanti Alekhya KottaVassilios Papalois
Aug 27, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Gregory L Hundemer, Manish M Sood
Aug 12, 2021·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Shigeru Shibata, Shunya Uchida
Aug 31, 2021·Der Nephrologe·Roland Schmitt
Oct 5, 2021·Der Internist·Vedat SchwengerAndrew Remppis
Oct 29, 2021·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Claudio BorghiGuido Grassi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

© 2021 Meta ULC. All rights reserved